Skip to main navigation

Home
News & Presentations
Governance
Financials
Stock Information
Resources

News Releases

News Releases

Year

Apr 12, 2021

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years

Mar 26, 2021

Arcutis Announces Updates to its Executive Team

Mar 18, 2021

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

Mar 17, 2021

Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021

Feb 25, 2021

Arcutis to Present at the Cowen 41st Annual Health Care Conference

Feb 18, 2021

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff

Feb 16, 2021

Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Feb 16, 2021

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

Feb 02, 2021

Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock

Feb 01, 2021

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 14

Print Page

RSS Feeds

Email Alerts

Search

information@arcutis.com

linkedin

Who We Are
Our Focus
Pipeline
Clinical Trials
Investors
Contact
News / Press
Legal Disclaimer

© 2021 Arcutis Biotherapeutics